Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

Benzinga Newsdesk www.benzinga.com Positive 58.5%

Neg 0% Neu 0% Pos 58.5%

Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $30.